Levosimendan Pretreatment for Weaning Patients From Cardio-Pulmonary Bypass
NCT ID: NCT00130871
Last Updated: 2007-02-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE2
60 participants
INTERVENTIONAL
2004-01-31
2006-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Prophylactic Administration of Levosimendan in Patients Undergoing Coronary Surgery
NCT01318460
Levosimendan and Myocardial Protection
NCT00610350
Short-term Endothelin A Receptor Blockade in Patients With On-pump CABG
NCT01658410
Coronary Artery Bypass Grafts or Percutaneous Coronary Intervention for High Risk Patients
NCT05534698
A Study of Anginera In Patients Undergoing Coronary Artery Bypass Graft (CABG) Surgery
NCT00364390
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
levosimendan
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Indication for on-pump coronary artery bypass surgery.
* Ejection fraction below 50%
Exclusion Criteria
* Previous coronary artery bypass surgery
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Orion Corporation, Orion Pharma
INDUSTRY
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Markku Salmenperä, MD
Role: PRINCIPAL_INVESTIGATOR
Helsinki University Central Hospital, Finland
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Helsinki University Central Hospital
Helsinki, , Finland
Turku University Central Hospital
Turku, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3001079
Identifier Type: -
Identifier Source: org_study_id
NCT00195832
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.